Related Experiment Video
Updated: May 18, 2026
Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
[Neuroendocrine pancreatic tumors and helpfulness of targeted therapies]
Thibaut Vaysse1, Romain Coriat, Géraldine Perkins
1CHU de Cochin Port-Royal, service de gastro-entérologue, 75014 Paris, France.
Abstract:
The neuroendocrine pancreatic tumors are rare tumors, but their incidence is constantly rising. Even if the management of these tumors has to be surgical as soon as possible, the disease is most often metastatic at the stage of the diagnostic. The prognostic and the therapeutic options differ from pancreatic adenocarcinoma. Available treatments have evolved over the last years with recent publications of studies that bring to light the benefits of targeted therapies in this pathology. This has resulted in modifications of both practices and either French and international guidelines. Therefore, we focus on the management of the grade 1 and grade 2 well-differentiated neuroendocrine pancreatic tumors as classified in new WHO classification of neuroendocrine neoplasms published in 2010.
Insights
Neuroendocrine pancreatic tumors are rising but often diagnosed at metastatic stages. Recent targeted therapies are improving management and guidelines for well-differentiated types.
Area of Science:
- Oncology
- Endocrinology
- Gastroenterology
Context:
- Neuroendocrine pancreatic tumors (NEPTs) are rare but increasing.
- Diagnosis often occurs at advanced metastatic stages.
- NEPTs have distinct prognoses and treatments compared to pancreatic adenocarcinoma.
Purpose:
- To review the management of grade 1 and grade 2 well-differentiated NEPTs.
- To incorporate recent advancements in targeted therapies.
- To align with updated WHO classification of neuroendocrine neoplasms (2010).
Summary:
- Focuses on well-differentiated, low-grade NEPTs (WHO grade 1 and 2).
- Highlights the shift towards targeted therapies.
- Discusses evolving clinical practices and guidelines.
Impact:
- Provides updated management strategies for NEPTs.
- Informs clinical decision-making for oncologists and endocrinologists.
- Contributes to improved patient outcomes through evidence-based treatment recommendations.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment: